CD44 in Bone Metastasis Development: A Key Player in the Fate Decisions of the Invading Cells?

[1]  Hongxi Xu,et al.  Osteoblasts and osteoclasts: an important switch of tumour cell dormancy during bone metastasis , 2022, Journal of Experimental & Clinical Cancer Research.

[2]  X. Zhang,et al.  Review old bone, new tricks , 2022, Clinical & Experimental Metastasis.

[3]  F. Gianfrancesco,et al.  The Osteoclast Traces the Route to Bone Tumors and Metastases , 2022, Frontiers in Cell and Developmental Biology.

[4]  Tomoko Fujita,et al.  The ELEANOR noncoding RNA expression contributes to cancer dormancy and predicts late recurrence of estrogen receptor‐positive breast cancer , 2022, Cancer science.

[5]  D. Weihs,et al.  Breast cancer stem cells: mechanobiology reveals highly invasive cancer cell subpopulations , 2022, Cellular and Molecular Life Sciences.

[6]  S. Batra,et al.  Chemokines network in bone metastasis: Vital regulators of seeding and soiling. , 2022, Seminars in cancer biology.

[7]  P. Varamini,et al.  Breast Cancer Bone Metastasis: A Narrative Review of Emerging Targeted Drug Delivery Systems , 2022, Cells.

[8]  J. Ban,et al.  Mechanisms, Diagnosis and Treatment of Bone Metastases , 2021, Cells.

[9]  F. Gao,et al.  The state of CD44 activation in cancer progression and therapeutic targeting , 2021, The FEBS journal.

[10]  S. Di Agostino,et al.  CD44v8-10 is a marker for malignant traits and a potential driver of bone metastasis in a subpopulation of prostate cancer cells , 2021, Cancer biology & medicine.

[11]  L. Qin,et al.  Characteristics of pre-metastatic niche: the landscape of molecular and cellular pathways , 2021, Molecular Biomedicine.

[12]  I. Holen,et al.  Bone Metastasis: Mechanisms, Therapies and Biomarkers. , 2020, Physiological reviews.

[13]  J. van Rheenen,et al.  Targeting dormant tumor cells to prevent cancer recurrence , 2020, The FEBS journal.

[14]  D. Krause,et al.  "Caught in the net" - the extracellular matrix of the bone marrow in normal haematopoiesis and leukaemia. , 2020, Experimental hematology.

[15]  Liang Li,et al.  Ninjurin 2 rs118050317 gene polymorphism and endometrial cancer risk , 2020, Cancer Cell International.

[16]  F. Francescangeli,et al.  Breast Cancer Stem Cells as Drivers of Tumor Chemoresistance, Dormancy and Relapse: New Challenges and Therapeutic Opportunities , 2019, Cancers.

[17]  Linda T. Senbanjo,et al.  Characterization of CD44 intracellular domain interaction with RUNX2 in PC3 human prostate cancer cells , 2019, Cell Communication and Signaling.

[18]  Binzhi Qian,et al.  Osteopontin as a multifaceted driver of bone metastasis and drug resistance. , 2019, Pharmacological research.

[19]  P. Lehenkari,et al.  Osteoclasts secrete osteopontin into resorption lacunae during bone resorption , 2019, Histochemistry and Cell Biology.

[20]  M. McDonald,et al.  Tumor Cell Dormancy and Reactivation in Bone: Skeletal Biology and Therapeutic Opportunities , 2019, JBMR plus.

[21]  B. Sharma,et al.  Targeted Nanomedicine to Treat Bone Metastasis , 2018, Pharmaceutics.

[22]  H. Zayed,et al.  Novel CD44-downstream signaling pathways mediating breast tumor invasion , 2018, International journal of biological sciences.

[23]  Hao Huang,et al.  Matrix Metalloproteinase-9 (MMP-9) as a Cancer Biomarker and MMP-9 Biosensors: Recent Advances , 2018, Sensors.

[24]  A. Maurizi,et al.  The Osteoclast in Bone Metastasis: Player and Target , 2018, Cancers.

[25]  C. Chen,et al.  The biology and role of CD44 in cancer progression: therapeutic implications , 2018, Journal of Hematology & Oncology.

[26]  M. Hou,et al.  Molecular Regulation of Bone Metastasis Pathogenesis , 2018, Cellular Physiology and Biochemistry.

[27]  C. Dass,et al.  Breast cancer bone metastases: pathogenesis and therapeutic targets. , 2018, The international journal of biochemistry & cell biology.

[28]  A. Teti,et al.  Osteomimicry: How the Seed Grows in the Soil , 2017, Calcified Tissue International.

[29]  S. Kousteni,et al.  The Osteoblastic Niche in Hematopoiesis and Hematological Myeloid Malignancies , 2017, Current Molecular Biology Reports.

[30]  Linda T. Senbanjo,et al.  CD44: A Multifunctional Cell Surface Adhesion Receptor Is a Regulator of Progression and Metastasis of Cancer Cells , 2017, Front. Cell Dev. Biol..

[31]  Nuno Bonito,et al.  Bone Metastases: An Overview , 2017, Oncology reviews.

[32]  D. Theodorescu,et al.  CD44: A metastasis driver and therapeutic target , 2016, Oncoscience.

[33]  E. Rankin,et al.  Hypoxic control of metastasis , 2016, Science.

[34]  M. Barbolina,et al.  Expression and Function of CD44 in Epithelial Ovarian Carcinoma , 2015, Biomolecules.

[35]  Hyung Keun Kim,et al.  AB139. The role of CD44 in the osteoblastic differentiation from mesenchymal stem cells. , 2015 .

[36]  V. Orian-Rousseau.  CD44 Acts as a Signaling Platform Controlling Tumor Progression and Metastasis , 2015, Front. Immunol..

[37]  Seok-Jun Kim,et al.  Cleaved CD44 intracellular domain supports activation of stemness factors and promotes tumorigenesis of breast cancer , 2015, Oncotarget.

[38]  Nawwaf S. Basakran.  CD44 as a potential diagnostic tumor marker , 2015, Saudi medical journal.

[39]  H. Daida,et al.  Increased extracellular and intracellular Ca²⁺ lead to adipocyte accumulation in bone marrow stromal cells by different mechanisms. , 2015, Biochemical and biophysical research communications.

[40]  Swati Pradhan-Bhatt,et al.  Hyaluronan: a simple polysaccharide with diverse biological functions. , 2014, Acta biomaterialia.

[41]  A. Cittadini,et al.  Cancer stem cells in colorectal cancer from pathogenesis to therapy: controversies and perspectives. , 2014, World journal of gastroenterology.

[42]  J. Sleeman,et al.  Opposing effects of high- and low-molecular weight hyaluronan on CXCL12-induced CXCR4 signaling depend on CD44 , 2013, Cell Death and Disease.

[43]  Hiroaki Nakamura,et al.  Cancer stem-like cell marker CD44 promotes bone metastases by enhancing tumorigenicity, cell motility, and hyaluronan production. , 2013, Cancer research.

[44]  Premkumar Vummidi Giridhar,et al.  CD44 integrates signaling in normal stem cell, cancer stem cell and (pre)metastatic niches , 2013, Experimental biology and medicine.

[45]  Aditi Gupta,et al.  Promising Noninvasive Cellular Phenotype in Prostate Cancer Cells Knockdown of Matrix Metalloproteinase 9 , 2013, TheScientificWorldJournal.

[46]  Aditi Gupta,et al.  Integrin αvβ3 and CD44 pathways in metastatic prostate cancer cells support osteoclastogenesis via a Runx2/Smad 5/receptor activator of NF-κB ligand signaling axis , 2012, Molecular Cancer.

[47]  G. Semenza,et al.  Hypoxia Regulates CD44 and Its Variant Isoforms through HIF-1α in Triple Negative Breast Cancer , 2012, PloS one.

[48]  F. O'Brien,et al.  Osteomimicry of Mammary Adenocarcinoma Cells In Vitro; Increased Expression of Bone Matrix Proteins and Proliferation within a 3D Collagen Environment , 2012, PloS one.

[49]  K. Pienta,et al.  Homing of Cancer Cells to the Bone , 2011, Cancer Microenvironment.

[50]  R. Markwald,et al.  Hyaluronan–CD44 interactions as potential targets for cancer therapy , 2011, The FEBS journal.

[51]  Yu-Chi Chen,et al.  Breast cancer metastasis to the bone: mechanisms of bone loss , 2010, Breast Cancer Research.

[52]  Eric Farrell,et al.  The role of hypoxia in bone marrow-derived mesenchymal stem cells: considerations for regenerative medicine approaches. , 2010, Tissue engineering. Part B, Reviews.

[53]  J. Kim,et al.  Alendronate Enhances Osteogenic Differentiation of Bone Marrow Stromal Cells: A Preliminary Study , 2009, Clinical orthopaedics and related research.

[54]  Chie-Pein Chen,et al.  Transforming growth factor-beta induces CD44 cleavage that promotes migration of MDA-MB-435s cells through the up-regulation of membrane type 1-matrix metalloproteinase. , 2009, International journal of cancer.

[55]  R. Stern.  Association between cancer and "acid mucopolysaccharides": an old concept comes of age, finally. , 2008, Seminars in cancer biology.

[56]  H. Iwase,et al.  Hypoxia-inducible factor 1α is closely linked to an aggressive phenotype in breast cancer , 2008, Breast Cancer Research and Treatment.

[57]  P. Kuo,et al.  Osteopontin: regulation in tumor metastasis , 2008, Cancer and Metastasis Reviews.

[58]  J. Lieberman,et al.  Tumor metastasis to bone , 2007, Arthritis research & therapy.

[59]  M. Rogers,et al.  Molecular Cancer Mechanisms of Osteopontin and Cd44 as Metastatic Principles in Prostate Cancer Cells , 2006 .

[60]  P. Johnston,et al.  The emerging role of CD44 in regulating skeletal micrometastasis. , 2006, Cancer letters.

[61]  M. Miyake,et al.  Exogenous hyaluronic acid enhances porcine parthenogenetic embryo development in vitro possibly mediated by CD44. , 2005, Theriogenology.

[62]  H. Saya,et al.  Mechanism and biological significance of CD44 cleavage , 2004, Cancer science.

[63]  P. Johnston,et al.  CD44 Potentiates the Adherence of Metastatic Prostate and Breast Cancer Cells to Bone Marrow Endothelial Cells , 2004, Cancer Research.

[64]  C. Isacke,et al.  The role of the CD44 transmembrane and cytoplasmic domains in co-ordinating adhesive and signalling events , 2003, Journal of Cell Science.

[65]  P. Johnston,et al.  CD44 Expression on prostate cancer cells correlates with adhesion to bone marrow endothelial cells. , 2003 .

[66]  M. P. Martegani,et al.  CD44s adhesive function spontaneous and PMA-inducible CD44 cleavage are regulated at post-translational level in cells of melanocytic lineage , 2003, Melanoma research.

[67]  B. Strooper,et al.  Presenilin-dependent γ-secretase activity mediates the intramembranous cleavage of CD44 , 2003, Oncogene.

[68]  C. Isacke,et al.  The hyaluronan receptor, CD44. , 2002, The international journal of biochemistry & cell biology.

[69]  É. Álvarez,et al.  Interaction of CD44 with Different Forms of Hyaluronic Acid. Its Role in Adhesion and Migration of Tumor Cells , 2002, Cell communication & adhesion.

[70]  M. Noda,et al.  Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. , 2001, The Journal of clinical investigation.

[71]  M. Noda,et al.  Osteopontin Deficiency Reduces Experimental Tumor Cell Metastasis to Bone and Soft Tissues , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[72]  M. Glimcher,et al.  Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. , 2000, Science.

[73]  L. Chung,et al.  Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment , 1999, The Prostate.

[74]  R. Kosaki,et al.  Overproduction of hyaluronan by expression of the hyaluronan synthase Has2 enhances anchorage-independent growth and tumorigenicity. , 1999, Cancer research.

[75]  A. Aruffo,et al.  Characterization of the Heparan Sulfate and Chondroitin Sulfate Assembly Sites in CD44* , 1999, The Journal of Biological Chemistry.

[76]  C. Giachelli,et al.  Structural Requirements for α9β1-Mediated Adhesion and Migration to Thrombin-Cleaved Osteopontin , 1998 .

[77]  N. Takahashi,et al.  Ezrin/Radixin/Moesin (ERM) Proteins Bind to a Positively Charged Amino Acid Cluster in the Juxta-Membrane Cytoplasmic Domain of CD44, CD43, and ICAM-2 , 1998, The Journal of cell biology.

[78]  Borland,et al.  Forms and functions of CD44 , 1998, Immunology.

[79]  J. Aubin,et al.  CD44 expression in fetal rat bone: in vivo and in vitro analysis. , 1996, Experimental cell research.

[80]  M. Glimcher,et al.  Receptor-Ligand Interaction Between CD44 and Osteopontin (Eta-1) , 1996, Science.

[81]  K. Bennett,et al.  CD44 isoforms containing exon V3 are responsible for the presentation of heparin-binding growth factor , 1995, The Journal of cell biology.

[82]  N. Sato,et al.  ERM family members as molecular linkers between the cell surface glycoprotein CD44 and actin-based cytoskeletons , 1994, The Journal of cell biology.

[83]  M. Miyasaka,et al.  A novel ligand for CD44 is sulfated proteoglycan. , 1994, International immunology.

[84]  J. Bell,et al.  Multiple variants of the human lymphocyte homing receptor CD44 generated by insertions at a single site in the extracellular domain. , 1992, The Journal of biological chemistry.

[85]  S. Jalkanen,et al.  Lymphocyte CD44 binds the COOH-terminal heparin-binding domain of fibronectin , 1992, The Journal of cell biology.

[86]  C. Fisher.  Metastasis , 1989, Ciba Foundation symposium.

[87]  I. Levinger,et al.  Life is three dimensional-as in vitro cancer cultures should be. , 2014, Advances in cancer research.

[88]  I. Schraufstatter,et al.  Hyaluronan in the healthy and malignant hematopoietic microenvironment. , 2014, Advances in cancer research.

[89]  G. van der Pluijm.  Epithelial plasticity, cancer stem cells and bone metastasis formation. , 2011, Bone.

[90]  C. Lynch.  Matrix metalloproteinases as master regulators of the vicious cycle of bone metastasis. , 2011, Bone.

[91]  R. Vago,et al.  Hyaluronan and mesenchymal stem cells: from germ layer to cartilage and bone. , 2011, Frontiers in bioscience.

[92]  T. Komori.  Regulation of osteoblast differentiation by Runx2. , 2010, Advances in experimental medicine and biology.

[93]  K. Iczkowski.  Cell adhesion molecule CD44: its functional roles in prostate cancer. , 2010, American journal of translational research.

[94]  D. Megías,et al.  Polarized MT1-MMP-CD44 interaction and CD44 cleavage during cell retraction reveal an essential role for MT1-MMP in CD44-mediated invasion. , 2009, Cell motility and the cytoskeleton.

[95]  G. Tuszynski,et al.  The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis , 2009, Pathology Oncology Research.

[96]  V. Castronovo,et al.  Transcriptome analysis reveals an osteoblast-like phenotype for human osteotropic breast cancer cells , 2006, Breast Cancer Research and Treatment.

[97]  L. Chung,et al.  Biologic and Therapeutic Implications of Osteomimicry and Epithelial-Mesenchymal Transition in Prostate Cancer , 2005 .

[98]  C. McCulloch,et al.  Analysis of intracellular osteopontin as a marker of osteoblastic cell differentiation and mesenchymal cell migration. , 1998, European journal of oral sciences.

[99]  K. Tanaka,et al.  CD 44 Variants but not CD 44 s Cooperate with b 1-containing Integrins to Permit Cells to Bind to Osteopontin Independently of Arginine-glycine-aspartic Acid , thereby Stimulating Cell Motility and Chemotaxis 1 , 1998 .

[100]  Ronit Vogt Sionov,et al.  CD44: structure, function, and association with the malignant process. , 1997, Advances in cancer research.

[101]  A. Pagliarulo,et al.  Advanced prostate cancer follow-up with prostate-specific antigen, prostatic acid phosphatase, osteocalcin and bone isoenzyme of alkaline phosphatase. , 1992, European urology.